Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 BreakoutsGlobal Report·Jul 9 at 05:02 AMBVS+5.51%ALT+6.86%
Altimmune shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $10 price target.benzinga_article·Jun 22 at 12:47 PMALT+6.86%
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data NearMarket Beat·Jun 10 at 08:05 AMALT+6.86%
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH TrialMarket Beat·Jun 4 at 10:08 PMALT+6.86%
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 | ALT Stock NewsStockTitan·May 28 at 02:00 AMALT+6.86%BIB+0.73%
Altimmune | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0Earnings Watch·May 13 at 03:23 PMALT+6.86%
Altimmune Q1 2026 Earnings Call: Complete Transcriptbenzinga_article·May 13 at 08:44 AMALT+6.86%FBT-0.26%
Altimmune | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0Earnings Watch·May 13 at 06:36 AMALT+6.86%
Altimmune Announces First Quarter 2026 Financial Results and Business Update | ALT Stock NewsStockTitan·May 12 at 10:30 PMALT+6.86%IBBQ+0.43%
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 | ALT Stock NewsStockTitan·May 12 at 10:20 PMALT+6.86%IBBQ+0.43%
Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from AnalystsMarket Beat·Apr 27 at 01:22 AMALT+6.86%SBIO+1.11%
